Search Results
Results 451 - 500 of 1438
< 5 6 7 8 9 10 11 12 13 14 15 >
Anselmetti Giovanni Carlo - - 2008
The aim of this study was to assess the efficacy of percutaneous cementoplasty (PC) with polymethylmethacrylate (PMMA) in painful extravertebral lytic bone metastases not responding to conventional therapy. Fifty patients (25 females), mean age 64.7 +/- 11.2 years, underwent PC after giving informed consent. Procedures were performed under fluoroscopy (1/50) ...
Dimopoulos M A - - 2009
BACKGROUND: Osteonecrosis of the jaw (ONJ) is a well-described complication of bisphosphonates use in patients with multiple myeloma (MM). We investigated whether the occurrence of ONJ decreased after the implementation of preventive measures in 128 patients with MM who received zoledronic acid. PATIENTS AND METHODS: Patients with MM who received ...
Mathioudakis Nestoras - - 2008
PURPOSE OF REVIEW: Description of the progresses related to the complications and treatment of adult-onset growth hormone deficiency. RECENT FINDINGS: Growth hormone deficiency in adults has gained attention as a clinical syndrome associated with increased morbidity and possibly mortality. Many studies have been conducted on the consequences of growth hormone ...
Iizuka Takahiro - - 2008
BACKGROUND: Bisphosphonates decrease bone resorption and bone formation. The excessive and prolonged suppression of bone turnover results in poor bone quality in the treatment of osteoporosis, although the relevant pharmacological benefits of bisphosphonates are widely known. Concerns have been raised about potential excessive suppression of bone turnover during long-term use. ...
Collaud Stéphane - - 2008
BACKGROUND: Few studies have reported changes of bone mineral density (BMD) after parathyroidectomy in patients with persistent hyperparathyroidism after renal transplantation (3 HPT). PATIENTS AND METHODS: We retrospectively analyzed 14 patients who underwent successful parathyroidectomy for 3 HPT and who had available BMD data before and after parathyroidectomy. RESULTS: Median ...
La Verde Nicla - - 2008
GOALS OF THE WORK: Osteonecrosis of the jaw (ONJ) is a severe complication of bisphosphonates treatment. Bisphosphonates reduce skeletal adverse events and give a clinical benefit to cancer patients. Therefore, it is necessary to identify appropriate procedures to reduce ONJ injures by using a successful monitoring program. In a retrospective ...
Hofmann W P - - 2008
The importance of osteoporosis as a complication of end-stage liver disease is well known. However, significant osteopenia may occur in earlier stages of chronic hepatitis C (CHC). Furthermore, antiviral therapy may influence bone metabolism. Thirty patients with CHC genotype 1 infection and without established cirrhosis were treated with peginterferon-alfa and ...
Ripamonti C I - - 2009
BACKGROUND: Screening of the oral cavity and dental care was suggested as mandatory preventive measures of osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BPs). We investigated the occurrence of ONJ before and after implementation of dental preventive measures when starting BP therapy. PATIENTS AND METHODS: Since April 2005, ...
Wang Shi-xiang - - 2008
BACKGROUND: Renal osteodystrophy is one of the commonest complications of chronic renal failure. It may have a severe impact on the quality of life of patients on maintenance dialysis therapy. Besides post-menopausal women and elderly people, the dialysis patients are another high risk group. But at present, there is no ...
Sng Kevin K - - 2008
BACKGROUND: Oesophageal perforation is uncommon, with controversy surrounding its optimal management. Our local experience shows a high incidence of oesophageal perforation secondary to ingested bones. METHODS: Fourteen patients with oesophageal perforation treated at Changi General Hospital in Singapore between January 1996 and December 2006 were retrospectively reviewed. RESULTS: The median ...
Graziani Filippo - - 2008
Alendronate is a bisphosphonate frequently used to reduce bone resorption. It has been used for osteoporosis, Paget's disease, and also as adjunctive therapy for periodontal disease. The aim of this study was to evaluate the effect of systemic alendronate with or without endoalveolar collagen sponge on vertical bone resorption after ...
Tucci Joseph R - - 2008
OBJECTIVE: To describe the effects of an infusion of zoledronic acid in a patient with Paget disease of bone (PD) who had been treated unsuccessfully with several other bisphosphonates. METHODS: The patient's treatment history is described, and his response to various bisphosphonates, including zoledronic acid, is discussed. RESULTS: The patient ...
Nordenström Erik - - 2009
BACKGROUND: Primary hyperparathyroidism (pHPT) is associated with decreased bone density and increased fracture risk. A significant number of pHPT patients have low calcium intake and suffer from vitamin deficiency. Thus, we adopted a policy of postoperative supplements with calcium and vitamin D after parathyroid surgery. In this study, we investigated ...
Lukan N - - 2008
The aim of this report was to answer the question how specific immunotherapy influences the antioxidant enzyme system in patients with respiratory allergy and in longer perspective to find markers suitable to assess the efficacy of treatment. In open prospective randomised study 28 patients (18 females and 10 males, age ...
Tekin Nilgun Solak - - 2008
BACKGROUND: High-dose isotretinoin has been reported to have adverse effects on bone mineral density (BMD); however, studies evaluating changes in BMD with isotretinoin therapy at different dosages and with varying treatment durations have produced conflicting results. OBJECTIVE: To investigate the effect of a standard, single course of isotretinoin therapy on ...
Nielsen Dorthe - - 2008
INTRODUCTION: Specific pharmacological treatment reduces the incidence of fractures significantly in patients with osteoporosis. Unfortunately, compliance with such therapy is low in clinical practice and is inversely related to educational level. We hypothesized that patients' knowledge of osteoporosis may be increased by a group-based multidisciplinary education programme. METHODS: Three hundred ...
Iwasaki Toshiyuki T Department of Pediatrics, Kitasato University School of Medicine, Kanagawa, Japan. - - 2008
The aim of the present paper was to investigate 20 pediatric patients with cerebral palsy and secondary osteoporosis and consider the efficacy, influence and index of treatment. A total of 10 boys and 10 girls, age 1-16 years (mean 7.6 years) with secondary osteoporosis and cerebral palsy treated for 6 ...
Scarpellini M - - 2008
BACKGROUND: The purpose of the present study was to determine relationship between disease activity, systemic markers of cartilage degradation, urinary C-terminal cross-linking telopeptides of type II collagen (uCTX-II), and bone degradation, urinary C-terminal cross-linking telopeptides of type I collagen (uCTX-I), structural progression of osteoarthritis (OA) and potential therapeutic efficacy of ...
Visvanathan S - - 2009
To evaluate the relationship between bone mineral density (BMD) and biomarkers of bone turnover and inflammation in patients with ankylosing spondylitis (AS) treated with infliximab. Patients (n = 279) were randomly assigned (3:8) to receive placebo or 5 mg/kg infliximab every 6 weeks through week 96. At week 24, placebo-treated ...
Moon Deok Hyun - - 2008
A long-term bench scale treatability study was performed to assess the ability to remediate chromite ore processing residue (COPR) using calcium polysulfide (CaS(5)). COPR materials were characterized with respect to particle size, pH, curing period and mineralogy. A stoichiometric ratio of sulfide species to hexavalent chromium (Cr(6+)) of 2 was ...
Brito Vinicius Nahime - - 2008
CONTEXT: Several factors can affect adult height (AH) of patients with gonadotropin-dependent precocious puberty (GDPP) treated with depot GnRH analogs. OBJECTIVE: Our objective was to determine factors influencing AH in patients with GDPP treated with depot GnRH analogs. PATIENTS: A total of 54 patients (45 girls) with GDPP treated with ...
Kawamata Akiko - - 2008
Osteoporosis is a major complication of Cushing's syndrome. The aim of the present study was to assess the chronologic effect of surgical cure on bone mineral density (BMD) in patients with Cushing's syndrome due to adrenal adenoma. BMD was examined in 28 patients before laparoscopic adrenalectomy; 17 patients with reduced ...
Alekna V - - 2008
Prospective study on patients with spinal cord injuries. To evaluate the loss of bone mineral density (BMD) in various body regions of patients with spinal cord injury (SCI) and its dependence on weight bearing activities during 2 years post injury. BMD of the whole body was measured in patients with ...
Miller Paul D - - 2008
Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor-kappa B ligand (RANKL), an essential mediator of osteoclast formation, function, and survival that has been shown to decrease bone turnover and increase bone mineral density (BMD) in treated patients. We assessed the long-term efficacy and safety ...
Garin I E - - 2008
PURPOSE: To review all patients with chondroblastoma treated in our hospital between 1993 and 2004. METHODS: Six men and 4 women aged 13 to 33 (mean, 21) years with histologically proven chondroblastomas were retrospectively reviewed through our tumour registry, patient records, radiographic and histopathologic reports. All patients underwent intralesional curettage ...
Kawahara Takashi - - 2008
We studied the short-term efficacy of alendronate, an oral bisphosphonates, on bone mineral density (BMD) during androgen deprivation therapy (ADT) in 45 nonmetastatic prostate cancer patients at the beginning of ADT (treatment group). All received alendronate five mg daily from the initiation of ADT. Lumber BMD was evaluated by dual ...
Malmgren Barbro - - 2008
BACKGROUND: Recent reports of osteonecrosis of the jaw (ONJ) after dental surgery in patients treated with second- and third-generation nitrogen-containing bisphosphonates instigated this retrospective study. As treatment with bisphosphonates in patients with osteogenesis imperfecta (OI) has become an important symptomatic therapy, especially for severe forms of the disease, we found ...
Joshi S - - 2008
BACKGROUND: Imatinib mesylate has shown promising results in chronic myeloid leukemia (CML) in all phases. This drug is an effective treatment for patients with CML in chronic phase as it induces hematological remission in nearly all patients and cytogenetic responses in many. The bone marrow changes produced by this drug ...
Kaminski Andrzej - - 2008
Five patients with atrophic or septic non-union of long bones were treated with free vascularised corticoperiosteal bone flaps. The patients had undergone an average of nine prior operations (range, 2-29). The treatment was combined with repeat internal fixation in four patients,. Treatment took place an average of 25.5 months (range ...
Pfeil Emily - - 2008
BACKGROUND: Hypogonadism is manifest in all age groups, and a growing elderly population is requiring treatment for testosterone deficiency, presenting new safety challenges, as many of these individuals present with comorbidities and significant risk profiles. OBJECTIVE: To discuss testosterone replacement modalities, their advantages and disadvantages, and provide a discussion of ...
Trikudanathan Subbulaxmi - - 2008
Glucocorticoids are taken by approximately 2% of the US adult population at any given time. The powerful anti-inflammatory and immunosuppressive benefits of these drugs must, however, be weighed against their multisystem adverse effects. Clinicians should always prescribe the lowest possible dose for the shortest possible time. Patients should be informed ...
Eastell Richard - - 2008
PURPOSE: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial (median follow-up, 68 months) has shown that adjuvant anastrozole has superior efficacy and better tolerability than tamoxifen. However, anastrozole reduces circulating estrogen, and low estradiol levels are associated with decreased bone mineral density (BMD) and increased fracture risk. It is ...
Mazzaglia Peter J - - 2008
OBJECTIVE: To analyze changes in the presentation of primary hyperparathyroidism over the last 3 decades. DESIGN: Retrospective review. SETTING: Tertiary referral center. PATIENTS: Three hundred patients undergoing parathyroidectomy for primary hyperparathyroidism, 100 each in the years 1985, 1995, and 2005. MAIN OUTCOME MEASURES: Analysis was performed based on patient age, ...
Badawi Manal A - - 2008
OBJECTIVE: To describe the case of a young Saudi male patient with long-term panhypopituitarism and pancytopenia attributable to poor adherence to androgen replacement therapy, which resolved after institution of testosterone treatment and recurred after another interval of poor adherence to recommended therapy. METHODS: We present the clinical and laboratory data ...
Camacho Pauline M - - 2008
OBJECTIVE: To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment. METHODS: A 75-year-old woman with hypophosphatasia was treated with ergocalciferol and calcium supplements for 2 years. She had sustained multiple spontaneous and low-trauma fractures since she ...
Sims K B - - 2008
Progressive skeletal disease accounts for some of the most debilitating complications of type 1 Gaucher disease. In this 48-month, prospective, non-randomized, open-label study of the effect of enzyme replacement therapy on bone response, 33 imiglucerase-naïve patients (median age 43 years with one or more skeletal manifestations such as osteopenia, history ...
Adami S - - 2008
None of the available osteoporosis therapies completely abolish the risk of fracture. Among 862 patients on treatment with antiresorptive agents (alendronate, risedronate, and raloxifene) for >1 year a fragility fracture was observed in 9.5%/year. This incidence is considerably higher than that observed in randomized clinical trials. INTRODUCTION: Available osteoporosis therapies ...
Coathup M - - 2008
An experimental sheep model was used for impaction allografting of 12 hemiarthroplasty femoral components placed into two equal-sized groups. In group 1, a 50:50 mixture of ApaPore hydroxyapatite bone-graft substitute and allograft was used. In group 2, ApaPore and allograft were mixed in a 90:10 ratio. Both groups were killed ...
Simsek Mehmet - - 2008
AIM: To evaluate the effects of hormone replacement therapy (HRT) on bone mineral density (BMD) in patients with or without COL1A1 Sp1 binding site polymorphism. METHODS: Non-smoking otherwise healthy postmenopausal women (n=111), who had not received any kind of HRT for at least 3 years (between 2002 and 2005) at ...
Watts Nelson B - - 2008
The first bisphosphonate (etidronate) was approved by the FDA in 1977; alendronate was approved in 1995 for the prevention and treatment of osteoporosis. Bisphosphonates have emerged as the agents of choice for the treatment of osteoporosis and have proved useful in the treatment of skeletal complications of malignancy (hypercalcemia, bone ...
Leslie William D - - 2008
The most widely used procedure for performing a BMD reproducibility assessment (same-technologist with simple repositioning on the same day) systematically underestimates precision error and will lead to over categorization of change in a large fraction of monitored patients. INTRODUCTION: The most common procedure for establishing the least significant change (LSC) ...
Grazio Simeon - - 2008
Long-term treatment of osteoporosis is required for optimal efficacy, but adherence to therapy is suboptimal with daily and weekly oral bisphosphonates. The aim of this study was to assess real-world persistence (long-term adherence) with weekly alendronate. Persistence data were collected according to World Health Organization criteria for the prior month ...
Stakkestad Jacob A - - 2008
Oral ibandronate is the first bisphosphonate licensed for once-monthly treatment of postmenopausal osteoporosis. The 2-year Monthly Oral iBandronate In LadiEs (MOBILE) registration study assessed bone mineral density (BMD) and markers of bone turnover and showed that monthly oral ibandronate was at least as effective and well tolerated as a 2.5-mg ...
Grzegorzewska Alicja E - - 2008
Variations in results concerning the influence of low molecular weight heparins (LMWHs) and antiplatelet drugs (APtDs) on bone mineral density (BMD) have led us to investigate whether dialysis patients receiving these drugs (group I) are characterized by a BMD different from that of patients not receiving such medications (group II). ...
Dickinson Brian P - - 2008
In older cleft patients, alveolar bone grafting may be associated with poor wound healing, graft exposure, recurrent fistula, and failure of tooth eruption. A new procedure using a resorbable collagen matrix with bone morphogenetic protein (BMP)-2 was compared with traditional iliac crest bone graft to close alveolar defects in older ...
Majima Takafumi - - 2008
OBJECTIVE: Although osteoporosis in men previously was relatively neglected, bisphosphonates have been strongly suggested as potent therapeutic agents. However, there are few studies on the effects of risedronate in male osteoporosis, especially in Japanese with primary osteoporosis. The aim of our study was to prospectively evaluate the effects of risedronate ...
Infante Cossío Pedro - - 2008
PURPOSE: To review the main clinical-radiographic, therapeutic, and preventive aspects of osteonecrosis related to intravenous bisphosphonate therapy in patients with multiple myeloma. MATERIALS AND METHODS: Between 2005 and 2006, we studied four patients with previous diagnosis of multiple myeloma treated with intravenous zoledronic acid, presenting nonhealing extraction sockets and intraoral ...
Avramidis Avraam - - 2008
Bisphosphonates have long been used with success in the treatment of Paget's disease of bone (PDB). The aim of this study was to evaluate the early (up to 3 months) and late (at 12 months) scintigraphic, biochemical, and clinical response to a single intravenous infusion of zoledronic acid (ZOL) in ...
Andiran Nesibe - - 2008
BACKGROUND: Cyclic intravenous pamidronate treatment is widely used for symptomatic therapy of osteogenesis imperfecta (OI). However, data after discontinuation are very limited. AIM: The results of cyclical pamidronate treatment in 14 patients with moderate/severe OI and follow up of six of them after discontinuation are presented to assess the effects ...
Ots Pilar Ma Samper - - 2008
Anemia is the most frequent hematological disturbance in cancer patients, with prevalence between 30% and 90%, depending on the type of tumor, the antitumor treatment, and other factors (infection, malnutrition, bleeding, tumor infiltration of the bone marrow). A number of erythropoietic agents have shown to be effective in increasing the ...
< 5 6 7 8 9 10 11 12 13 14 15 >